Drug reference

lorlatinib

Mosby’s 2024 Nursing Drug Reference

Source: Mosby’s 2024 Nursing Drug Reference
PDF pages: 816

Overview

Names and pronunciation

(lor-la′ti-nib) Lorbrena

PDF page 816

Functional class

Func. class.: Antineoplastic

PDF page 816

Uses

USES: Metastatic ALK-positive non– small-cell lung cancer (NSCLC) with disease progression on either alectinib or ceritinib as the first ALK inhibitor for metastatic disease, or disease pro- gression on crizotinib and at least one other ALK inhibitor for metastatic dis- ease

PDF page 816

Safety

Contraindications

CONTRAINDICATIONS: Hyper sensitivity

PDF page 816

Dose and formulations

Dosage and routes

DOSAGE AND ROUTES • Adult: PO 100 mg daily until disease progression or unacceptable toxicity

PDF page 816

Available forms

Available forms: Tabs 25, 100 mg

PDF page 816

Dose text by age group

Adult

• Adult: PO 100 mg daily until disease progression or unacceptable toxicity

PDF page 816

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

lorlatinib

Mosby’s 2024 Nursing Drug Reference

Source: Mosby’s 2024 Nursing Drug Reference
PDF pages: 816

Overview

Names and pronunciation

(lor-la′ti-nib) Lorbrena

PDF page 816

Functional class

Func. class.: Antineoplastic

PDF page 816

Uses

PDF page 816

Safety

Contraindications

CONTRAINDICATIONS: Hyper sensitivity

PDF page 816

Dose and formulations

Dosage and routes

DOSAGE AND ROUTES • Adult: PO 100 mg daily until disease progression or unacceptable toxicity

PDF page 816

Available forms

Available forms: Tabs 25, 100 mg

PDF page 816

Dose text by age group

Adult

• Adult: PO 100 mg daily until disease progression or unacceptable toxicity

PDF page 816

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.